EMA seeks comments on stability data requirements for variations
This article was originally published in SRA
The European Medicines Agency has issued for consultation a draft guideline on the stability data it expects manufacturers to generate to support a variation to a marketing authorisation1.
You may also be interested in...
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
New medicines under evaluation at the European Medicines Agency.
The European Medicine Agency has recommended extending the therapeutic indication of a raft of drugs that are already authorized in the EU.